Practical considerations for the use of IL-23p19 inhibitors in inflammatory bowel disease: how to choose between them and why it matters? - Summary - MDSpire
Advertisement
Practical considerations for the use of IL-23p19 inhibitors in inflammatory bowel disease: how to choose between them and why it matters?
To summarize the current clinical evidence on anti-IL23p19 therapies and provide practical guidance for their use in inflammatory bowel disease (IBD) management.
Key Findings:
Three IL-23p19 inhibitors (Guselkumab, Risankizumab, Mirikizumab) are approved for moderate-to-severe Crohn's disease (CD) and ulcerative colitis (UC).
Guselkumab offers a unique subcutaneous induction regimen, proving non-inferiority to intravenous induction.
Key factors for selecting an anti-IL23p19 agent include patient preference, IBD phenotype, coexisting conditions, and previous therapy exposure.
Interpretation:
The emergence of selective IL-23 inhibitors represents a significant advancement in IBD treatment, allowing for personalized therapy based on individual patient needs and characteristics.
Limitations:
Further real-world studies are needed to assess the effectiveness of anti-IL23p19 therapies in complex disease phenotypes.
The long-term implications of dual mechanisms of action, particularly for Guselkumab, remain incompletely understood.
Conclusion:
Anti-IL23p19 inhibitors may become first-line therapies for moderate-to-severe IBD, especially in patients with IL-23 driven comorbidities. Their combination with other therapies is being explored to enhance outcomes.
